A Director Of bluebird bio Inc. (BLUE) Sells 4290.0 Shares


bluebird bio Inc. (NASDAQ:BLUE) saw a downside of -0.16% to close Monday at $6.19 after subtracting -$0.01 on the day. The 5-day average trading volume is 7,560,460 shares of the company’s common stock. It has gained $7.78 in the past week and touched a new high 1 time within the past 5 days. An average of 4,258,605 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 3,756,680.

BLUE’s 1-month performance is -16.58% or -$0.99 on its low of $5.68 reached on 01/20/23. The company’s shares have touched a 52-week low of $2.87 and high of $8.58, with the stock’s rally to the 52-week high happening on 01/13/23. YTD, BLUE has lost -10.55% or -$0.73 and has reached a new high 6 times. However, the current price is down -27.86% from the 52-week high price.

Top 5 Undervalued Stocks To Own In 2023

Microchip Maker Releases "World's Most Powerful Data Center CPU". It could allow the company who manufactures it to lead the industry as the global microchip shortage continues into the coming year. We've put together a free research report that explains all the details. Not only will you find out why analysts believe this chip manufacturer could lead the pack, you will also discover four more potential winners for the coming year.

Click here to download your Free Research Report…


Insider Transactions

BLUE stock investors last saw insider trading activity on Jan 11.Leschly Nick (Director) most recently sold 4,290 shares at $7.80 per share on Jan 11. This transaction cost the insider $33,480. Chief Medical Officer, Colvin Richard A, sold 557 shares at a price of $7.80 on Jan 11. Then, on Jan 11, President and CEO Obenshain Andrew sold 3,178 shares at a price of $7.80 per share. This transaction amounted to $24,802.

Valuation Metrics

BLUE stock has a beta of 0.95. Moving on to other valuation ratios, the trailing price-to-sales (P/S) ratio is 96.08 while the price-to-book (PB) in the most recent quarter is 3.17.

The firm’s gross profit as reported stood at -$35.2 million against revenue of $3.66 million.

Earnings Surprise

For the quarterly period ending September 29 this year, bluebird bio Inc.’s cash and short-term investments amounted to $73.16 million against total debt of $278.21 million. Net income and sales went down compared to those figures reported in the previous quarter. Net income shrunk -215.87% to -$76.52 million, while revenue of -$100.14 million was -30.87% off the previous quarter. Analysts expected BLUE to announce -$1.12 per share in earnings in its latest quarter, but it posted -$0.94, representing a 16.10% surprise. EBITDA for the quarter stood at more than -$83.39 million. BLUE stock balance sheet for the quarter ending September 29 shows that total liabilities totaled 361.24 million, with total debt at $278.21 million. Shareholders hold equity totaling $82.91 million.

Let’s look briefly at bluebird bio Inc. (BLUE) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 23 January was 33.71% to suggest the stock is trending Neutral, with historical volatility in this time period at 110.28%.

The stock’s 5-day moving average is $6.32, reflecting a -21.55% or -$1.70 change from its current price. BLUE is currently trading -20.23% above its 20-day SMA, +4.92% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 by -16.01% and SMA200 by+24.80%.

Stochastic %K and %D was 12.72% and 11.09% and the average true range (ATR) pointed at 0.60. The RSI (14) points at 38.19%, while the 14-day stochastic is at 17.96% with the period’s ATR at 0.59. The stock’s 9-day MACD Oscillator is pointing at -0.95 and -1.14 on the 14-day charts.

Analyst Ratings

In the most recent analyst report for bluebird bio Inc. (NASDAQ: BLUE), Barclays upgraded it to an Equal weight rating. They previously had an Underweight rating on the stock. Analysts offering their rating for BLUE stock have a consensus rating for the stock as Hold. Currently, 2 brokerage advisors rate BLUE as a “sell,”, while 8 advise that investors “Hold.” 0 analysts have rated the stock as underweight. 1 rates the stock as overweight while 0 have offered a “buy” rating.

What is BLUE’s price target for the next 12 months?

Analysts have a consensus price target ranging from a low of $3.00 and a high of $10.00, with their median price target at $8.00. Looking at these predictions, the average price target given by analysts is for bluebird bio Inc. (BLUE) stock is $7.33.


Please enter your comment!
Please enter your name here